This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Multicenter, Placebo-Controlled, Double-blind Trial

Fluoxetine Bulimia Nervosa Collaborative Study Group

Arch Gen Psychiatry. 1992;49(2):139-147.

Abstract
• Bulimia nervosa represents a serious public health problem in the United States. We performed an 8-week, double-blind trial comparing fluoxetine hydrochloride (60 and 20 mg/d) with placebo in 387 bulimic women treated on an outpatient basis. Fluoxetine at 60 mg/d proved superior to placebo in decreasing the frequency of weekly binge-eating and vomiting episodes at end point. Fluoxetine at 20 mg/d produced an effect between that of the 60mg/d dosage and that of placebo. Depression, carbohydrate craving, and pathologic eating attitudes and behaviors also improved significantly with fluoxetine, with the higher dosage again showing a more robust effect than the lower dosage. Several adverse events (ie, insomnia, nausea, asthenia, and tremor) occurred significantly more frequently with fluoxetine (60 or 20 mg/d) than with placebo. However, there was no statistically significant difference among treatment groups in the proportion of patients discontinuing the study because of adverse events.

Author Affiliations
From the Fluoxetine Bulimia Nervosa Collaborative Study Group.

Footnotes
Accepted for publication April 8, 1991.

Reprint requests to Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center 2146, Indianapolis, IN 46285 (Louise R. Levine, MD).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Fluoxetine treatment of anorexia nervosa: important but disappointing results.
Crow
JAMA 2006;295:2659-2660.
FULL TEXT  

Eating Disorders
Yager et al.
Focus 2005;3:503-510.
ABSTRACT | FULL TEXT  

Treatment of Bulimia Nervosa in a Primary Care Setting
Walsh et al.
Am. J. Psychiatry 2004;161:556-561.
ABSTRACT | FULL TEXT  

Gut Feminism
WILSON
differences 2004;15:66-94.
 

Bulimia Nervosa
Mehler
NEJM 2003;349:875-881.
FULL TEXT  

Putting the research into practice
Hay
BMJ 2003;327:381-381.
FULL TEXT  

Treatment of Bulimia Nervosa:: Psychological and Psychopharmacologic Considerations
Phillips et al.
Journal of Adolescent Research 2003;18:261-279.
ABSTRACT  

Eating Disorders in the Adolescent Population:: Future Directions
Pratt et al.
Journal of Adolescent Research 2003;18:297-317.
ABSTRACT  

Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's disease
Ikeda et al.
J. Neurol. Neurosurg. Psychiatry 2002;73:371-376.
ABSTRACT | FULL TEXT  

Linkage analysis of anorexia nervosa incorporating behavioral covariates
Devlin et al.
Hum Mol Genet 2002;11:689-696.
ABSTRACT | FULL TEXT  

A Placebo-Controlled Study of Fluoxetine in Continued Treatment of Bulimia Nervosa After Successful Acute Fluoxetine Treatment
Romano et al.
Am. J. Psychiatry 2002;159:96-102.
ABSTRACT | FULL TEXT  

Topiramate for Bulimia Nervosa in Epilepsy
KNABLE
Am. J. Psychiatry 2001;158:322--323.
FULL TEXT  

Obesity: What Mental Health Professionals Need to Know
Devlin et al.
Am. J. Psychiatry 2000;157:854-866.
ABSTRACT | FULL TEXT  

Placebo-Controlled Trial of Sertraline in the Treatment of Binge Eating Disorder
McElroy et al.
Am. J. Psychiatry 2000;157:1004-1006.
ABSTRACT | FULL TEXT  

Treatment of chronic fatigue syndrome with nefazodone.
NEUMEISTER et al.
Am. J. Psychiatry 1999;156:797-798.
FULL TEXT  

Fluvoxamine in the Treatment of Binge-Eating Disorder: A Multicenter Placebo-Controlled, Double-Blind Trial
Hudson et al.
Am. J. Psychiatry 1998;155:1756-1762.
ABSTRACT | FULL TEXT  

Outcome Assessment and Clinical Improvement in Panic Disorder: Evidence From a Randomized Controlled Trial of Fluoxetine and Placebo
Michelson et al.
Am. J. Psychiatry 1998;155:1570-1577.
ABSTRACT | FULL TEXT  

Guided Self-Change for Bulimia Nervosa Incorporating Use of a Self-Care Manual
Thiels et al.
Am. J. Psychiatry 1998;155:947-953.
ABSTRACT | FULL TEXT  

Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics
Goldstein and Goodnick
J Psychopharmacol 1998;12:55-S87.
ABSTRACT  

Models to Conceptualize Risk Factors for Bulimia Nervosa
Halmi
Arch Gen Psychiatry 1997;54:507-508.
ABSTRACT  

Decreased Serotonin Function in Bulimia Nervosa
Jimerson et al.
Arch Gen Psychiatry 1997;54:529-534.
ABSTRACT  

Fluoxetine in the Treatment of Premenstrual Dysphoria
Steiner et al.
NEJM 1995;332:1529-1534.
ABSTRACT | FULL TEXT  

The SSRIs: advantages, disadvantages and differences
Lane et al.
J Psychopharmacol 1995;9:163-178.
ABSTRACT  

Fluoxetine
Gram
NEJM 1994;331:1354-1361.
FULL TEXT  

First step in managing bulimia nervosa: controlled trial of therapeutic manual
Treasure et al.
BMJ 1994;308:686-689.
ABSTRACT | FULL TEXT  

Psychiatry
Freedman and Stahl
JAMA 1992;268:403-405.
ABSTRACT